NovaBridge Will Present Givastomig Data in October
The company will share clinical findings on its cancer therapy at the 2026 ESMO Congress in Madrid.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Does the announcement of new clinical trial data increase your trust in cancer research progress?
NovaBridge Biosciences will present updated clinical data on its bispecific antibody, givastomig, at the European Society for Medical Oncology Congress on October 25, 2026. The therapy is being tested for use in HER2-negative advanced or metastatic gastroesophageal adenocarcinoma.
Why it matters
The company aims to use these clinical results to advance givastomig toward registrational development in the first-line treatment of metastatic gastroesophageal adenocarcinoma. The FDA has already granted the drug Fast Track Designation to help accelerate its development path.
Givastomig is a Claudin 18.2 x 4-1BB bispecific antibody currently in a global Phase 2 study identified as NCT07432295. The forthcoming data, categorized as presentation number 2945P, will detail its performance when used with nivolumab and chemotherapy.
The players
NovaBridge Biosciences
This Rockville, Maryland-based biopharmaceutical company focuses on developing bispecific antibodies for cancer treatment.
Samuel J. Klempner
He is the clinical investigator responsible for presenting the updated research findings on givastomig at the ESMO Congress.
The details
Givastomig is designed to conditionally activate T cells through the 4-1BB signaling pathway within the tumor microenvironment. The upcoming presentation will highlight its use in combination therapy, marking a significant step in NovaBridge Biosciences' research efforts.
Timeline
The ESMO Congress 2026 takes place in Madrid, Spain, from October 23 to October 27, 2026.
Samuel J. Klempner is scheduled to present the givastomig clinical study data on October 25, 2026.
The Big Picture
The clinical progression of givastomig follows the regulatory framework established by the U.S. Food and Drug Administration's Fast Track Designation process. This classification is intended to expedite the development and review of drugs treating serious conditions with unmet medical needs.
The potential advancement of this treatment could eventually offer a new therapeutic option for patients diagnosed with HER2-negative gastroesophageal adenocarcinoma. Future clinical results will determine if this combination therapy will be viable for broader use in standard oncology care.
The takeaway
Patients and oncologists should monitor upcoming conference results to understand the efficacy of new bispecific antibody combinations. These developments represent a shift toward more targeted immune-modulating cancer treatments.
Further reading
For more on current research and developments in oncology, visit the Cancer section.
Live Poll
Does the announcement of new clinical trial data increase your trust in cancer research progress?
